Clinical trials: Adult Depression
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00798707
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Where
- 78 sites in United States, Japan
- Volunteers
- 709 people
- Sponsor
- Pfizer
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Major Depressive Disorder
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.
- Trial name
- NCT03310281
- Testing
- HOLD: Videogame
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Akili Interactive Labs, Inc.
Major Depressive Disorder (MDD)
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive…
- Trial name
- NCT06958692
- Testing
- Dextromethorphan and Bupropion Sustained-Release Tablets
- Where
- China
- Volunteers
- 388 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Postpartum Depression
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial…
- Trial name
- NCT03924492
- Testing
- ZULRESSO (brexanolone) injection
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Postpartum Depression
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the…
- Trial name
- NCT02978326
- Testing
- SAGE-217 15/20 mg Oral Solution, SAGE 217 30 mg Capsules
- Where
- 27 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biogen
Major Depressive Disorder
A Long-Term Safety Study of ALKS 5461
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
- Trial name
- NCT02141399
- Testing
- ALKS 5461
- Where
- 158 sites in United States, Australia and 6 more
- Volunteers
- 1,485 people
- Sponsor
- Alkermes, Inc.
Unipolar Depression
Transcranial Direct Current Stimulation for Depression
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.
- Trial name
- NCT07042217
- Testing
- transcranial direct current stimulation (tDCS) and mindfulness instruction
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical
Major Depressive Disorder
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design.
- Trial name
- NCT00887224
- Testing
- Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg
- Where
- 90 sites in United States, Canada and 12 more
- Volunteers
- 874 people
- Sponsor
- Pfizer
Bipolar Disorder
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder.
- Trial name
- NCT00081380
- Testing
- Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
- Where
- 94 sites in United States, Canada
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Depression
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression.
- Conditions
- Major Depressive Disorder, Depression, Healthy
- Trial name
- NCT06570369
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Depressive Disorder, Major
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire I (NCT03039192)
- Testing
- Esketamine, Standard of Care
- Where
- 56 sites in United States, Bulgaria and 9 more
- Volunteers
- 226 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
- Trial name
- NCT04442490
- Testing
- SAGE-217
- Where
- 39 sites in United States
- Volunteers
- 543 people
- Sponsor
- Biogen
Major Depressive Disorder, Anxiety
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.
- Trial name
- NCT00621270
- Testing
- BCI-540
- Where
- 16 sites in Canada
- Volunteers
- 115 people
- Sponsor
- BrainCells Inc.
Major Depressive Disorder, Post Traumatic Stress Disorder
ALTO-100 in MDD and/or PTSD
The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
- Trial name
- NCT05117632
- Testing
- ALTO-100 PO tablet
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder (MDD)
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
- Trial name
- NCT00057239
- Testing
- Radafaxine
- Where
- 29 sites in United States
- Volunteers
- 546 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
ALTO-300 in Depression (ALTO-300-004)
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
- Trial name
- NCT05157945
- Testing
- ALTO-300 PO Tablet
- Where
- 4 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alto Neuroscience
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
- Trial name
- NCT04830215
- Testing
- Brexpiprazole
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.